Retina specialist
Vitreoretinal Consultants
New York, New York
Final Thoughts on Retinal Disease Treatments and Outcomes
Experts wrap up their discussion by highlighting key takeaways on the treatment of retinal diseases with anti-vascular endothelial growth factor (Anti-VEGF) therapies.
Read More
Emerging Gene Therapies for Retinal Diseases
Experts discuss emerging gene therapies for age-related macular degeneration (AMD) or diabetic macular edema (DME) and key end points considerations.
Other Emerging Retinal Disease Therapies
Experts discuss prospective therapies for age-related macular degeneration (AMD) or diabetic macular edema (DME) treatment.
High Dose Aflibercept as Emerging Therapy for Retinal Diseases
Experts discuss the recent PULSAR and PHOTON studies with high dose aflibercept (8mg) and how they educate patients about this treatment approach.
Efficacy of Faricimab in Clinical Trails
Experts discuss clinical trials on the efficacy of faricimab and how they utilize this therapy in their practice.
Step Therapy for Patients With DME
Experts discuss insurer mandated step therapy and how to navigate treatment options for patients with diabetic macular edema (DME).
Key Findings of DRCR Protocol AC Study
Experts discuss the recent DRCR Protocol AC study comparing aflibercept monotherapy vs bevacizumab first therapy for patients with diabetic macular edema (DME).
Key Findings of Protocol T Study
Experts discuss the results of Protocol T study comparing anti-vascular endothelial growth factor (Anti-VEGF) agents for the treatment of diabetic macular edema (DME).
Unique Challenges of DME Treatment
Experts discusses the unique challenges managing the care of patients with diabetic macular edema (DME).
Prospective Therapies and Treatment Strategies for nAMD
Experts discuss prospective therapies and improved outcome targets for patients with neovascular age-related macular degeneration (nAMD).
Treat and Extend Strategy for Aflibercept
Experts discuss their experience using the treat and extend strategy with aflibercept and their clinical advice when administering treatment.
Long-Term Treatment Experience with Aflibercept
Experts discuss the long-term efficacy and safety of aflibercept in the treatment of neovascular age-related macular degeneration (nAMD).
Applying CATT Study Results in Real World
Experts discuss the comparison of age-related macular degeneration treatments trials (CATT) and how today’s retina specialists can apply the results in their daily practice.
Managing Suboptimal Responders to Anti-VEGF Treatment
Experts discuss how they define suboptimal responders to anti-vascular endothelial growth factor (Anti-VEGF) treatment and how they manage the care of those patients.
Current Treatment Options for nAMD
Experts offer clinical advice on identifying and managing suboptimal responders on anti-vascular endothelial growth factor (Anti-VEGF) treatment.
Significance of SRF vs IRF in nAMD
Experts discuss the management of subretinal fluid (SRF) and intraretinal fluid (IRF) in patients with neovascular age-related macular degeneration (nAMD).
Markers of Disease Progression in nAMD Patients
Veeral Sheth, MD, MBA, FASRS, FACS, offers clinical advice on marking disease progression in neovascular age-related macular degeneration (nAMD).
Treat and Extend Strategy for Anti-VEGF Injections
Experts offer their clinical experience and advice for applying a treat and extend strategy with anti-vascular endothelial growth factor (Anti-VEGF) injections.
Real-World Long-Term Safety Data of Anti-VEGF Agents
Experts discuss safety data of anti-vascular endothelial growth factor (Anti-VEGF) agents while highlighting the importance of sharing this information with patients and relevant care providers.
Patient and Cross-Care Education Strategies for AMD and DME
Experts discuss strategies for educating patients, fellows, and shared-care providers on therapies and prospective outcomes for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).
Barriers to Optimal Treatment Outcomes
Experts discuss barriers that prevent optimal outcomes for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).
Overview of Anti-VEGF Treatments for AMD and DME
Experts provide an overview of anti-vascular endothelial growth factor (Anti-VEGF) treatment for patients with age-related macular degeneration (AMD) or diabetic macular edema (DME).
